Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance
    Anavex Expands IP With Blarcamesin U.S. Patent Issuance

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015498/29248/en/Anavex-Life-Sciences-Announces-Issuance-of-Blarcamesine-ANAVEX-2-73-Composition-of-Matter-U-S-Patent-Expanding-its-Intellectual-Property-Portfolio.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Anavex's Alzheimer Treatment Result Published In Journal
    Anavex's Alzheimer Treatment Result Published In Journal

    15 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/15/3009934/29248/en/Anavex-Life-Sciences-Announces-Peer-Reviewed-Publication-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-The-Journal-of-Prevention-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    15 Jan 2025
    Share Share
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease
    Blarcamesine Receives EMA Filing Acceptance for Alzheimer’s Disease

    23 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/23/3001118/29248/en/Blarcamesine-Receives-EMA-Filing-Acceptance-for-Treatment-of-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    23 Dec 2024
    Share Share
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data
    Anavex to Report Blarcamesine Phase IIb/III Alzheimer’s Data

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993663/29248/en/Anavex-Life-Sciences-to-Report-New-Long-Term-Oral-Blarcamesine-Phase-IIb-III-Alzheimer-s-Disease-Data-at-J-P-Morgan-2025-Healthcare-Conference.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript
    Anavex Life's Acceptance of Blarcamesine Phase IIb/III Data Manuscript

    25 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/25/2986572/29248/en/Anavex-Life-Sciences-Announces-Acceptance-of-Peer-Reviewed-Manuscript-of-Oral-Blarcamesine-Phase-IIb-III-Data-in-a-Reference-Alzheimer-s-Disease-Journal.html

    GLOBENEWSWIRE
    25 Nov 2024
    Share Share
    NANOBIOTIX to Attend Investor Conferences in November
    NANOBIOTIX to Attend Investor Conferences in November

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972317/0/en/NANOBIOTIX-to-Participate-in-Multiple-Investor-Conferences-in-November.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share